ERCC1 and non-small cell lung carcinoma: Several studies describe predictive markers of response for NSCLC cell lines, asexpression of the excision repair cross-complementation group 1 (ERCC1) gene forplatinum compounds [8] or the epidermal growth factor receptor (EGFR) mutationalstatus for the EGFR tyrosine-kinase inhibitors (gefitinib and erlotinib) [9]; [10].